Our Pricing

Mounjaro Discount Code UK: In Stock with Fast Delivery

Published on: June 03, 2026

Searching for a mounjaro discount code uk online with guaranteed stock availability? At Cured Pharmacy, we offer genuine UK-licensed Mounjaro (tirzepatide) pens from £124.99 with your discount code WEIGHTLOSSNEW providing £20 off first order using code WEIGHTLOSSNEW

How Mounjaro Discount Code UK Works at Cured Pharmacy

Using your Mounjaro discount code WEIGHTLOSSNEW is straightforward at Cured Pharmacy. After completing your free online consultation with our UK-registered prescribers, you'll receive £20 off first order using code WEIGHTLOSSNEW

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed from our GPhC-registered facility (9012511), guaranteeing you receive genuine UK-licensed Mounjaro pens with full patient information leaflets and storage guidance. Unlike some online pharmacies that show prices only after consultation, we display transparent upfront pricing so you know exactly what you'll pay before starting your assessment.

Why Mounjaro Is in Stock When Other Pharmacies Face Shortages

The UK has experienced significant Mounjaro supply challenges since its launch, with many pharmacies struggling to maintain consistent stock levels. At Cured Pharmacy, we've established direct relationships with licensed UK wholesalers and implemented robust inventory management systems to ensure continuous availability across all Mounjaro doses.

Our stock monitoring system updates in real-time, and we only accept new consultations when we can guarantee fulfilment within 1-2 working days. This means when you see Mounjaro listed as in stock on our website, you can proceed with confidence knowing your prescription will be dispensed and dispatched promptly after prescriber approval.

Guaranteed Stock Availability

We maintain stock of all Mounjaro KwikPen doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg) to support patients throughout their entire treatment journey. If a specific dose becomes temporarily unavailable, our clinical team will contact you before processing your consultation to discuss alternative timing or suitable alternatives like Wegovy, ensuring you're never left without appropriate weight management support.

Clinical Evidence: How Mounjaro Delivers Superior Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

The landmark SURMOUNT-1 trial demonstrated that patients receiving the 15mg Mounjaro dose achieved an average 22.5% body weight reduction over 72 weeks, compared to 2.4% with placebo [1]. At the 10mg dose, participants lost an average of 21.1% of their body weight, whilst even the lower 5mg maintenance dose produced 15.0% average weight reduction [1]. These results significantly exceeded those seen with semaglutide-based treatments in head-to-head comparisons.

In the SURMOUNT-3 trial, patients who had already lost weight through lifestyle interventions maintained and enhanced their results when starting Mounjaro, with 79.3% of participants maintaining at least 80% of their initial weight loss at 72 weeks [2]. This evidence supports Mounjaro's role not just in initial weight reduction but in long-term weight maintenance, addressing one of the most challenging aspects of obesity treatment.

Who Can Use Mounjaro in the UK

NICE guidance supports the use of GLP-1 receptor agonists for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. During your consultation, our UK prescribers assess your medical history, current medications, BMI, and weight loss goals to determine if Mounjaro is clinically appropriate for you. Mounjaro is not suitable during pregnancy, for patients with a personal or family history of medullary thyroid carcinoma, or those with multiple endocrine neoplasia syndrome type 2.

Mounjaro vs Wegovy: Comparing Your Weight Loss Options

Both Mounjaro and Wegovy are injectable weight loss treatments licensed in the UK, but they work through different mechanisms and produce different clinical outcomes. Wegovy contains semaglutide, a GLP-1 receptor agonist that achieved 14.9% average weight loss in the STEP-1 trial [4], whilst Mounjaro's dual GIP/GLP-1 mechanism produced up to 22.5% average weight reduction in comparable trial populations [1].

The choice between these treatments depends on several factors assessed during your consultation. Some patients prefer Wegovy's lower starting price point, whilst others prioritise Mounjaro's superior efficacy data. Both medications require once-weekly subcutaneous injection and follow similar dose escalation schedules to minimise gastrointestinal side effects. Your UK prescriber will discuss your medical history, previous weight loss attempts, budget considerations, and treatment goals to recommend the most suitable option.

How to Use Your Mounjaro Discount Code and Complete Your Assessment

Starting your Mounjaro treatment at Cured Pharmacy takes under 3 minutes. Click 'Start Assessment' on our Mounjaro product page, where you'll complete a clinical questionnaire covering your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered prescribers review every consultation individually, typically within 2-4 hours during working days.

If your prescriber approves Mounjaro as clinically appropriate, you'll receive an email confirmation with a link to complete your order. Enter discount code WEIGHTLOSSNEW at checkout to receive £20 off first order using code WEIGHTLOSSNEW

Each Mounjaro KwikPen comes with comprehensive patient information, including injection technique guidance, storage instructions (refrigerate at 2-8°C before first use), and advice on managing potential side effects. Our pharmacy team remains available on (+44) 116 4646009 if you have questions about your medication or need support during treatment.

Ongoing Prescription Management

Mounjaro treatment typically involves dose escalation every 4 weeks, starting at 2.5mg and increasing to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg depending on your response and tolerability. We send reminder emails before your current supply runs out, allowing you to complete a follow-up consultation for your next dose. Your discount code applies only to your first order, but our everyday pricing remains the lowest guaranteed in the UK across all subsequent prescriptions.

Managing Side Effects and Maximising Your Results

The most common side effects reported in Mounjaro clinical trials were gastrointestinal in nature, including nausea (reported by 29-33% of participants), diarrhoea (21-23%), constipation (17-19%), and vomiting (9-12%) [1]. These effects were typically mild to moderate, most frequent during dose escalation, and diminished over time as patients adapted to treatment.

To minimise gastrointestinal symptoms, our prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and allowing your body to adjust to each dose for the full 4 weeks before escalating. If side effects become troublesome, your prescriber may recommend staying at your current dose longer or, in rare cases, reducing to the previous dose temporarily.

Mounjaro works most effectively when combined with sustainable lifestyle modifications. Clinical trials included patients who followed reduced-calorie diets and increased physical activity alongside medication [1]. Our clinical team can provide guidance on evidence-based nutrition approaches and realistic activity goals that complement your Mounjaro treatment, though we don't replace the personalised support available through NHS weight management programmes or registered dietitians.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wadden, T. A., Chao, A. M., Machineni, S., et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomised trial. The Lancet, 402(10407), 1097–1109. https://doi.org/10.1016/S0140-6736(23)01479-X [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro is a prescription-only medication and its suitability must be determined by a qualified healthcare professional based on your individual medical history and circumstances. Weight loss results vary between individuals, and the clinical trial data cited represents average outcomes in controlled study populations. Always consult a qualified healthcare professional before starting any new medication or weight management programme.